Belumosudil for chronic GVHD, mechanistic insights into VITT, and factors driving molecular response in IFNα-treated MPNs

episode

Blood Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

The Songs of John Farnham: A Living Legend | Tony Cochrane (23.09.26) 7 min · 23 Sep 2026 · Whateley

Las 10 de Erazno, el Chokolatazo, Parodias, 1h 29m · 23 Sep 2026 · Erazno y La Chokolata El Podcast

Steve Hilton & Spencer Pratt: Fixing California, Cheaper Gas, Ballot Fraud & CA Republicans 55 min · 23 Sep 2026 · All-In with Chamath, Jason, Sacks & Friedberg

Optics of Alastair Clarkson's brunt sacking | The Eminently Sensible Phil Davis (23.09.26) 1 min · 23 Sep 2026 · Whateley

The Eminently Sensible Phil Davis | Whateley (23.09.26) 13 min · 23 Sep 2026 · Whateley

The impact of Zak Butters' homecoming | The Eminently Sensible Phil Davis (23.09.26) 1 min · 23 Sep 2026 · Whateley

Report any issue

Source

Recorded02 Dec 2021

Publisherfeeds.transistor.fm ↗

Handlerec:11742110

Show notes

First on today’s podcast, we’ll review results of a randomized phase 2 study demonstrating that inhibition of ROCK2 with belumosudil is well tolerated and effective in patients with steroid-refractory graft-versus-host disease. Next, we’ll review the work of researchers who have uncovered new insights into the immunopathogenesis of vaccine-induced immune thrombotic thrombocytopenia. And we’ll close with a report of a prospective longitudinal analysis that elucidates the dynamics of mutated hematopoietic stem and progenitor cells during therapy with interferon-alpha in patients with BCR-ABL1 negative myeloproliferative neoplasms.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in